| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2882738 | The Annals of Thoracic Surgery | 2006 | 8 Pages |
Abstract
Chemotherapy resistance is prevalent among NSCLC clinical cell cultures. This may account for the small survival seen with empiric adjuvant chemotherapy. The use of viable tumor culture for in vitro chemoresistance testing should be considered when formulating a plan of adjuvant therapy for resected NSCLC. Future trials comparing patient survival after tailored versus empiric adjuvant therapy appear justified.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Thomas A. MD, PhD, Rodney J. MD, Robert J. MD, Ricardo S. MD, Ricardo J. PhD,